

<p style="text-align: center;">Notice of References Cited</p>	Application/Control No. 10/606,632	Applicant(s)/Patent Under Reexamination TAKAOKA ET AL.	
	Examiner Nancy L. Zhang	Art Unit 1614	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2002/0013334	01-2002	Robl et al.	514/291
*	B	US-2003/0073729	04-2003	Kitahara et al.	514/369
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Mizukami J, Taniguchi T., "The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP", Biochem Biophys Res Commun. 1997 Nov 7;240(1):61-4.
	V	Fukui Y, et. al., "A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAY obese mice", Diabetes. 2000 May;49(5):759-67.
	W	Devasthale et. al., "Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities", J Med Chem. 2005 Mar 24;48(6):2248-50.
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.